In Vivo Tumor Vasculature Targeting of CuS@MSN Based Theranostic Nanomedicine

Overview

Journal ACS Nano

Publisher American Chemical Society

Specialty Biotechnology

Date 2015 Apr 7

PMID 25843647

Citations 48

Authors

Feng Chen

Hao Hong

Shreya Goel

Stephen A Graves

Hakan Orbay

Emily B Ehlerding

Sixiang Shi

Charles P Theuer

Robert J Nickles

Weibo Cai

Affiliations

Soon will be listed here.

Abstract

Actively targeted theranostic nanomedicine may be the key for future personalized cancer management. Although numerous types of theranostic nanoparticles have been developed in the past decade for cancer treatment, challenges still exist in the engineering of biocompatible theranostic nanoparticles with highly specific in vivo tumor targeting capabilities. Here, we report the design, synthesis, surface engineering, and in vivo active vasculature targeting of a new category of theranostic nanoparticle for future cancer management. Water-soluble photothermally sensitive copper sulfide nanoparticles were encapsulated in biocompatible mesoporous silica shells, followed by multistep surface engineering to form the final theranostic nanoparticles. Systematic in vitro targeting, an in vivo long-term toxicity study, photothermal ablation evaluation, in vivo vasculature targeted imaging, biodistribution and histology studies were performed to fully explore the potential of as-developed new theranostic nanoparticles.

Citing Articles

Photothermal Coating on Zinc Alloy for Controlled Biodegradation and Improved Osseointegration.

Hsu Y, He Y, Zhao X, Wang F, Yang F, Zheng Y Adv Sci (Weinh). 2025; 12(9):e2409051.

PMID: 39807526 PMC: 11884568. DOI: 10.1002/advs.202409051.

Cuproptosis-based layer-by-layer silk fibroin nanoplatform-loaded PD-L1 siRNA combining photothermal and chemodynamic therapy against metastatic breast cancer.

Li Z, Cheng L, Xu X, Jia R, Zhu S, Zhang Q Mater Today Bio. 2024; 29:101298.

PMID: 39469315 PMC: 11513806. DOI: 10.1016/j.mtbio.2024.101298.

Multifunctional mesoporous silica nanoparticles for biomedical applications.

Xu B, Li S, Shi R, Liu H Signal Transduct Target Ther. 2023; 8(1):435.

PMID: 37996406 PMC: 10667354. DOI: 10.1038/s41392-023-01654-7.

Nanomedicine in cancer therapy.

Fan D, Cao Y, Cao M, Wang Y, Cao Y, Gong T Signal Transduct Target Ther. 2023; 8(1):293.

PMID: 37544972 PMC: 10404590. DOI: 10.1038/s41392-023-01536-y.

Nanoparticles labeled with gamma-emitting radioisotopes: an attractive approach for in vivo tracking using SPECT imaging.

Ahmadi M, Emzhik M, Mosayebnia M Drug Deliv Transl Res. 2023; 13(6):1546-1583.

PMID: 36811810 DOI: 10.1007/s13346-023-01291-1.

References

Shen D, Yang J, Li X, Zhou L, Zhang R, Li W . Biphase stratification approach to three-dimensional dendritic biodegradable mesoporous silica nanospheres. Nano Lett. 2014; 14(2):923-32. DOI: 10.1021/nl404316v. View

Zhang Y, Hong H, Nayak T, Valdovinos H, Myklejord D, Theuer C . Imaging tumor angiogenesis in breast cancer experimental lung metastasis with positron emission tomography, near-infrared fluorescence, and bioluminescence. Angiogenesis. 2013; 16(3):663-74. PMC: 3706271. DOI: 10.1007/s10456-013-9344-y. View

Xie J, Lee S, Chen X . Nanoparticle-based theranostic agents. Adv Drug Deliv Rev. 2010; 62(11):1064-79. PMC: 2988080. DOI: 10.1016/j.addr.2010.07.009. View

Wu W, Ichihara G, Hashimoto N, Hasegawa Y, Hayashi Y, Tada-Oikawa S . Synergistic effect of bolus exposure to zinc oxide nanoparticles on bleomycin-induced secretion of pro-fibrotic cytokines without lasting fibrotic changes in murine lungs. Int J Mol Sci. 2015; 16(1):660-76. PMC: 4307267. DOI: 10.3390/ijms16010660. View

Tian Q, Tang M, Sun Y, Zou R, Chen Z, Zhu M . Hydrophilic flower-like CuS superstructures as an efficient 980 nm laser-driven photothermal agent for ablation of cancer cells. Adv Mater. 2011; 23(31):3542-7. DOI: 10.1002/adma.201101295. View

Tian Q, Jiang F, Zou R, Liu Q, Chen Z, Zhu M . Hydrophilic Cu9S5 nanocrystals: a photothermal agent with a 25.7% heat conversion efficiency for photothermal ablation of cancer cells in vivo. ACS Nano. 2011; 5(12):9761-71. DOI: 10.1021/nn203293t. View

Pan L, He Q, Liu J, Chen Y, Ma M, Zhang L . Nuclear-targeted drug delivery of TAT peptide-conjugated monodisperse mesoporous silica nanoparticles. J Am Chem Soc. 2012; 134(13):5722-5. DOI: 10.1021/ja211035w. View

Hong H, Zhang Y, Severin G, Yang Y, Engle J, Niu G . Multimodality imaging of breast cancer experimental lung metastasis with bioluminescence and a monoclonal antibody dual-labeled with 89Zr and IRDye 800CW. Mol Pharm. 2012; 9(8):2339-49. PMC: 3500677. DOI: 10.1021/mp300277f. View

Hong H, Yang K, Zhang Y, Engle J, Feng L, Yang Y . In vivo targeting and imaging of tumor vasculature with radiolabeled, antibody-conjugated nanographene. ACS Nano. 2012; 6(3):2361-70. PMC: 3314116. DOI: 10.1021/nn204625e. View

10.

Chen F, Cai W . Tumor vasculature targeting: a generally applicable approach for functionalized nanomaterials. Small. 2014; 10(10):1887-93. PMC: 4126500. DOI: 10.1002/smll.201303627. View

11.

Zhou M, Zhang R, Huang M, Lu W, Song S, Melancon M . A chelator-free multifunctional [64Cu]CuS nanoparticle platform for simultaneous micro-PET/CT imaging and photothermal ablation therapy. J Am Chem Soc. 2010; 132(43):15351-8. PMC: 2966020. DOI: 10.1021/ja106855m. View

12.

Benezra M, Penate-Medina O, Zanzonico P, Schaer D, Ow H, Burns A . Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J Clin Invest. 2011; 121(7):2768-80. PMC: 3223837. DOI: 10.1172/JCI45600. View

13.

Cai W, Wu Y, Chen K, Cao Q, Tice D, Chen X . In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3. Cancer Res. 2006; 66(19):9673-81. DOI: 10.1158/0008-5472.CAN-06-1480. View

14.

Muthu M, Leong D, Mei L, Feng S . Nanotheranostics - application and further development of nanomedicine strategies for advanced theranostics. Theranostics. 2014; 4(6):660-77. PMC: 3982135. DOI: 10.7150/thno.8698. View

15.

Blackwell K, Burstein H, Storniolo A, Rugo H, Sledge G, Aktan G . Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol. 2012; 30(21):2585-92. DOI: 10.1200/JCO.2011.35.6725. View

16.

Manchun S, Dass C, Sriamornsak P . Targeted therapy for cancer using pH-responsive nanocarrier systems. Life Sci. 2012; 90(11-12):381-7. DOI: 10.1016/j.lfs.2012.01.008. View

17.

Chen F, Ehlerding E, Cai W . Theranostic nanoparticles. J Nucl Med. 2014; 55(12):1919-22. PMC: 4255955. DOI: 10.2967/jnumed.114.146019. View

18.

Cai W, Zhang X, Wu Y, Chen X . A thiol-reactive 18F-labeling agent, N-[2-(4-18F-fluorobenzamido)ethyl]maleimide, and synthesis of RGD peptide-based tracer for PET imaging of alpha v beta 3 integrin expression. J Nucl Med. 2006; 47(7):1172-80. PMC: 1704081. View

19.

Zhan Q, Qian J, Liang H, Somesfalean G, Wang D, He S . Using 915 nm laser excited Tm³+/Er³+/Ho³+- doped NaYbF4 upconversion nanoparticles for in vitro and deeper in vivo bioimaging without overheating irradiation. ACS Nano. 2011; 5(5):3744-57. DOI: 10.1021/nn200110j. View

20.

Orbay H, Zhang Y, Hong H, Hacker T, Valdovinos H, Zagzebski J . Positron emission tomography imaging of angiogenesis in a murine hindlimb ischemia model with 64Cu-labeled TRC105. Mol Pharm. 2013; 10(7):2749-56. PMC: 3836864. DOI: 10.1021/mp400191w. View